ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

2021 P38 Mitogen - Activated Protein (MAP) Kinase Inhibitors Pipeline Insight Report - ResearchAndMarkets.com

December 30, 2021 GMT

DUBLIN--(BUSINESS WIRE)--Dec 30, 2021--

The “P38 Mitogen - Activated Protein (MAP) Kinase Inhibitors - Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in P38 mitogen-activated protein (MAP) kinase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

ADVERTISEMENT

P38 mitogen-activated protein (MAP) kinase inhibitors Emerging Drugs Chapters

This segment of the P38 mitogen-activated protein (MAP) kinase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

P38 mitogen-activated protein (MAP) kinase inhibitors Emerging Drugs

ARRY-371797: Pfizer

PF 07265803 is an orally active, small molecule, non-opioid analgesic that inhibits P38 mitogen-activated protein (MAP) kinase inhibitors, being developed by Pfizer for treatment of dilated cardiomyopathy due to a Lamin A/C gene mutation. It is being evaluated in Phase III stage of development for the treatment of dilated cardiomyopathy.

Losmapimod: Fulcrum therapeutics/ GlaxoSmithKline

Losmapimod is a selective p38?/? mitogen activated protein kinase (MAPK) inhibitor that was exclusively in-licensed from GSK by Fulcrum Therapeutics following Fulcrum’s discovery of the role of p38?/? inhibitors in the reduction of DUX4 expression and an extensive review of known compounds. Utilizing its proprietary product engine, FulcrumSeekT, Fulcrum discovered that inhibition of p38?/? reduced expression of the DUX4 gene in muscle cells derived from patients with FSHD. Although losmapimod has never previously been explored in muscular dystrophies, it has been evaluated in more than 3,600 subjects in clinical trials across multiple other indications, including in several Phase 2 trials and a Phase 3 trial. No safety signals were attributed to losmapimod in any of these trials. Losmapimod has been granted U.S. Food and Drug Administration (FDA) Fast Track designation and Orphan Drug Designation for the treatment of FSHD.

P38 mitogen-activated protein (MAP) kinase inhibitors: Therapeutic Assessment

ADVERTISEMENT

This segment of the report provides insights about the different P38 mitogen-activated protein (MAP) kinase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in P38 mitogen-activated protein (MAP) kinase inhibitors

There are approx. 8+ key companies which are developing the therapies for P38 mitogen-activated protein (MAP) kinase inhibitors. The companies which have their P38 mitogen-activated protein (MAP) kinase inhibitors drug candidates in the most advanced stage, i.e. phase III include Pfizer.

Phases

This report covers around 8+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

P38 mitogen-activated protein (MAP) kinase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous
  • Intravenous
  • Intramuscular
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Peptides
  • Polymer
  • Small molecule
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

P38 mitogen-activated protein (MAP) kinase inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses P38 mitogen-activated protein (MAP) kinase inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging P38 mitogen-activated protein (MAP) kinase inhibitors drugs.

P38 mitogen-activated protein (MAP) kinase inhibitors Report Insights

  • P38 mitogen-activated protein (MAP) kinase inhibitors Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

P38 mitogen-activated protein (MAP) kinase inhibitors Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing P38 mitogen-activated protein (MAP) kinase inhibitors drugs?
  • How many P38 mitogen-activated protein (MAP) kinase inhibitors drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of P38 mitogen-activated protein (MAP) kinase inhibitors?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the P38 mitogen-activated protein (MAP) kinase inhibitors therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for P38 mitogen-activated protein (MAP) kinase inhibitors and their status?
  • What are the key designations that have been granted to the emerging drugs?

Companies Mentioned

  • Pfizer
  • EIP Pharma
  • Fulcrum Therapeutics
  • GeneOne Life Science
  • Array BioPharma
  • Eli Lilly and Company
  • Chiesi Farmaceutici
  • TopiVert
  • Kinarus AG

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/2pawqt

View source version on businesswire.com:https://www.businesswire.com/news/home/20211230005221/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 12/30/2021 11:06 AM/DISC: 12/30/2021 11:07 AM

http://www.businesswire.com/news/home/20211230005221/en